Efficacy and safety of Shufeng Huashi formula for post-infectious cough: study protocol for a randomized control trial - Report - MDSpire

Efficacy and safety of Shufeng Huashi formula for post-infectious cough: study protocol for a randomized control trial

  • By

  • Xinyi Zhang

  • Yirun Li

  • Yuxin Han

  • Hongchun Zhang

  • June 1, 2026

  • 0 min

Share

Clinical Report: Assessment of Shufeng Huashi for Post-Infectious Cough

Overview

This report outlines a randomized controlled trial designed to evaluate the effectiveness and safety of the Shufeng Huashi formula in treating post-infectious cough (PIC). The study aims to provide evidence for a therapeutic approach that may improve patient outcomes in this prevalent condition.

Background

Post-infectious cough (PIC) is a common complication following respiratory infections, significantly affecting patients' quality of life. Current treatment options are limited and often associated with side effects, highlighting the need for effective alternatives. Traditional Chinese Medicine (TCM) offers potential benefits in managing PIC, warranting further investigation into its efficacy and safety.

Data Highlights

This study will involve 120 participants, randomly assigned to receive either the Shufeng Huashi formula or a placebo for 14 days. Primary and secondary outcomes will be measured to assess cough relief and symptom severity.

Key Findings

  • Post-infectious cough affects 11-25% of adults after respiratory infections.
  • Current pharmacological treatments for PIC show limited efficacy and significant side effects.
  • Traditional Chinese Medicine has demonstrated potential in improving cough duration and quality of life.
  • The Shufeng Huashi formula is hypothesized to provide effective relief with a favorable safety profile.
  • This trial aims to generate evidence to support TCM in clinical practice for PIC management.

Clinical Implications

The findings from this trial may inform clinical practice by providing evidence for the use of the Shufeng Huashi formula as a viable treatment option for post-infectious cough. If proven effective, it could enhance patient care and reduce reliance on conventional medications with adverse effects.

Conclusion

The ongoing trial of the Shufeng Huashi formula represents a significant step towards validating Traditional Chinese Medicine in the treatment of post-infectious cough. Results may lead to improved therapeutic strategies for this common condition.

Related Resources & Content

  1. Liu, Z., et al., Frontiers in Medicine, 2026 -- Correction: Investigation of the active compounds and pharmacological mechanisms of Qufengxuanfei decoction in the treatment of chronic cough
  2. Frontiers in Medicine, 2026 -- Efficacy of pulmonary rehabilitation combined with minimal-dose adjunctive TCM (Shen Yi Capsules and Hua Chan Su) in improving postoperative outcomes for non-small cell lung cancer: a randomized controlled trial
  3. Frontiers in Cardiovascular Medicine, 2026 -- Efficacy and safety of FangJiHuangQi granule in patients with heart failure: a protocol of randomized, placebo-controlled trial
  4. WAO - ARIA consensus on chronic cough: Executive summary, PMC, 2025
  5. 2025 American Cough Conference | Lung, Springer Nature Link
  6. Frontiers in Cardiovascular Medicine — Efficacy and safety of Shenqi Yangxin formula in patients with stable coronary artery disease based on CCTA: rationale, design, and study protocol for a randomized, double-blind, placebo-controlled study
  7. WAO - ARIA consensus on chronic cough: Executive summary - PMC
  8. 2025 American Cough Conference | Lung | Springer Nature Link

Original Source(s)

Related Content